Healthcare Providers and Pharmaceutical Companies Expected to See 20% Increase in Investment in Antimicrobial Stewardship Programs Over the Next 1-2 Years Due to Evidence of Cost Savings and Demand for Effective Resistance Management.
BMYCVSHCAMRKPFEUNHWBA
Statements (2)
- Bullish
The Healthcare Sector Will Likely See Increased Investment In companies developing antimicrobial stewardship programs and technologies in the coming years Due To the abstract's emphasis on the need for guidelines addressing antimicrobial resistance (AMR), which is expected to drive demand for solutions that promote appropriate antimicrobial use.
- Bullish
Healthcare Providers Will Likely See Increased Investment In Antimicrobial Stewardship Programs in the coming years Due To the abstract's emphasis on the critical role of pharmacists in optimizing antimicrobial use and reducing resistance in intensive care units.